myirislogo
24 October, 2019 02:42 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
Infosys 650.75 1.16
Tata Motors 132.65 0.57
Tata Power 60.80 2.62
Adani Ports 396.25 5.85
State Bank O 275.50 1.87
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Cadila Healthcare Limited
Cadila Healthcare Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:532321NSE:CADILAHCBloomberg:CDH@INReuters:CADI.BO
Market Lot: 1Face Value: 1ISIN Demat: INE010B01027
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
11-FEB-19 Zydus Cadila has received the final approval from the USFDA to market Carbamazepine Extended-Release Tablets USP (US RLD - Tegretol XR), 100 mg, 200 mg, and 400 mg. It will be manufactured at the group???s formulations manufacturing facility at Moraiya, Ahmedabad. 21-JAN-19 Zydus Cadila has received the tentative approval from the USFDA to market Esomeprazole Magnesium Delayed-Release Capsules (US RLD-NEXIUM). It will be manufactured...   More..
Business Profile Future Plans
CEO Talk
Cadila Healthcare Ltd, the homegrown pharma major that pioneered the concept of brand positioning in the Indian pharma market in the 1980s, is now poised for a new phase of export-led growth.  Pankaj R Patel
One To One
Recent news
Latest News
Zydus Cadila receives final USFDA approvals for 2 drugs  -IRIS 22-Feb-19
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Dec-2017(9)31-Mar-2017(12)31-Mar-2016(12)
Net sales 43675.0042883.0064365.20
Other Income1774.005844.001341.10
Total Income45449.0048727.0065706.30
Cost of goods sold32187.0040345.0044923.70
OPBDIT13262.008382.0020782.60
PAT8476.007994.0019773.30
Gross Block---
Equity capital--1024.00
EPS (Rs.)---
DPS (Rs.)---
BV (Rs.)---
P/E range (x)---
Debt / Equity (x)---
Operating margin (% of OI)29.217.231.6
Net margin (% of OI)18.616.430.1
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Zydus Tower
Satellite Cross Roads
Sarkhej - Gandhinagar Highway
Ahmedabad
Gujarat-380 015
PHONE
(079) 2686 8100
FAX
(079) 2686 2365/ 66
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer